Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Shareholder Meeting (November 2014)
27 slides from Avita Medical's shareholder meeting presentation, Nov 21, 2014
Slide 1: Annual General Meeting
Annual General Meeting 21 November 2014 1
Slide 2: Disclaimer
Disclaimer This presentation may include forward‐looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward looking statement
Slide 3: CEO Address Outline
CEO Address Outline o Where we are today • Clarity and unity across Board and Management • On track with commercialisation strategy o Progress since 2013 AGM • Established unique selling propositions (USPs) in focused clinical indications • A leader amongst peers in regenerative cell‐based therapeut
Slide 4: Where we are Today
Where we are Today o Leadership aligned and poised to facilitate our transition to next stage of growth • Shareholder concerns acknowledged and acted upon • Board/management issues from 2013 resolved • Team united and energized o Platform regenerative technology • Implementing regenerative medicine
Slide 5: Regenerative Platform Technology Serves as Catalyst
Regenerative Platform Technology Serves as Catalyst Autologous Cell Harvesting Devices (single‐use) o Rapid (30 min) creation of a regenerative suspension, comprised of the patient’s own skin cells and associated signaling factors, in an easy‐to‐use bedside kit for the clinician o Delivers a suspens
Slide 6: Intellectual Property
Intellectual Property Avita Medical’s regenerative technology platform is protected by a family of patents, granted (expiring 2022) and pending(*). Claim s Area Claim s Area Australia US Method, composition & Method* Japan US apparatus Brazil* US Composition* Austria US Belgium Europe Apparatus* Fra
Slide 7: Historical Challenges
Historical Challenges o The clinical indications targeted cannot be met with a single product • Different aspects of the platform technology’s mechanism of action feature more prominently in different clinical areas • Key messages must vary according to unmet need in each clinical area o Limited pro
Slide 8: Launch of focused Regenerative Products
Launch of focused Regenerative Products rePAIR ** Burn/Trauma Acute Wounds Centers reSTART Hospital‐based Chronic Wounds / (Vascular/Plastics) Reconstruction reSTORE Private Clinic Cosmesis (Aesthetics/Plastics) **High‐capacity: for treatment up to 1,920 cm2 (from 320 cm2) 8
Slide 9: Clarity Achieved with FDA means Defined Development Path Forward
Clarity Achieved with FDA means Defined Development Path Forward o Approved expanded evaluation of ReCell in burns and broadened eligibility criteria for study participants • Resolved historical delays with recruitment • Positions ReCell for wider commercial opportunity • Trial participation now pos
Slide 10: Global Distribution
Global Distribution Avita Medical Europe Cambridge, UK Avita Medical Americas Los Angeles Direct Avita Medical Distributor Asia Pacific Australia Regulatory trials in progress 10
Slide 11: Strategic Partnering Initiative
Strategic Partnering Initiative Pursue Commercial Partnerships (By Indication / Call point / Geography) • Deliver Product • Build Evidence Base • Secure Approvals • Demonstrate Commercial Success (selected markets) examples of key players in selected markets ‐ for illustration purposes only 11
Slide 12: Respiratory Product Line: Update Summary
Respiratory Product Line: Update Summary o Management explored divestiture options and has now resolved to reinvigorate the line with renewed focus and specific initiatives o An increased investment in the line with the following initiatives is anticipated to stimulate additional revenue, as the res
Slide 13: How the past 12 months represent a transformational period
How the past 12 months represent a transformational period 13
Slide 14: Meaningful Progress Achieved
Meaningful Progress Achieved Clinical – delivering on high‐level evidence (randomised controlled trials, RCTs) o Acute Wounds • Revised US Burns RCT aligns with USP; in addition to regulatory approval, will support NICE data requirements and clinical marketing worldwide • US Compassionate Use Cohort
Slide 15: Meaningful Progress Achieved (continued)
Meaningful Progress Achieved (continued) o Sales & Marketing resources restructured to drive strategy • Added marketing personnel • Built out new UK sales staff • New USPs focused on clinical unmet needs and viable opportunities • New, differentiated products launched, with associated re‐branding an
Slide 16: Understanding the "Avita Opportunity"
Understanding the “Avita Opportunity” Avita is Uniquely Positioned for Growth 16
Slide 17: Regenerative Medicine at a Glance
Regenerative Medicine at a Glance It is estimated that there are more than 700 companies worldwide with a regenerative medicine focus The Alliance for Regenerative Medicine considers 418 of those companies as leaders in the space There are 247 therapeutically focused companies in the space 2014 Rege
Slide 18: Our Standing in the Regenerative Medicine Space
Our Standing in the Regenerative Medicine Space Cell‐Based Therapeutics o Avita’s Regenerative platform spans Primary Cell and Progenitor Cell Therapeutics o Of the 247 companies in the Regenerative Medicine Therapeutic space there are only 28 marketed products o ReCell has a first‐mover advantage o
Slide 19: US Phase III Status (Phase IV outside US)
US Phase III Status (Phase IV outside US) o There are 383 clinical trials progressing in the Primary Cell‐Based & Stem/Progenitor Cell‐ Based segments o Only 25 of those trials are in Phase III (6.5%) o ReCell’s recently modified US Phase III burns trial now paves a clear pathway 2014 Regenerative M
Slide 20: Pharmaceutical and Large-Cap Biotech Perspective on Regenerative Medicine
Pharmaceutical and Large-Cap Biotech Perspective on Regenerative Medicine Pharma and Large‐Cap Biotechs Engagement in Regenerative Medicine Survey Respondents Allergan, Amgen, Baxter, Biogen Idec, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Johnson & Johnson, Merck Serono, Novartis, Novo Nordisk,
Slide 21: A highly active space: Recent M & A Activity
A highly active space: Recent M & A Activity 2014 Regenerative Medicine Annual Industry Report, Alliance for Regenerative Medicine 21
Slide 22: Market Opportunity
Market Opportunity Effectively unlimited… Selected Opportunity Indications US UK, FR, DE, IT Aus China Market Size* e.g., excludes plastic and pop. 316M pop. 271M pop. 23M pop. 1.4B maxillofacial surgeries (11.4% diabetes1) (8% diabetes, avg1) (5.1% diabetes1) (9.3% diabetes1) Chronic DFU 2 9.0M 5.5
Slide 23: A look forward
A look forward 23
Slide 24: The Plan Moving Forward
The Plan Moving Forward A clear path ahead, strategic and targeted execution Expand ReCell use Continue to develop in Acute Wounds Capitalise on Aesthetics Chronic Wounds (burns /trauma) Key Drivers: Key Drivers: Key Drivers: • US Burns RCT • Recently completed , • Venous Leg Ulcer Pilot RCT Will s
Slide 25: Key Upcoming Milestones
Key Upcoming Milestones Australia approval CE‐Mark Australia approval China approval Ulcer indication 2Q2015 4Q2015 1Q2016 4Q2016 VLU Pilot RCT & DFU Feasibility studies complete 4Q2015 3Q2015 1Q2016 3Q2016 CE‐Mark Australia approval China approval DE Aesthetics 2Q2015 4Q2015 1Q2016 study complete 3
Slide 26: Today's Avita: Well-Positioned for Growth
Today’s Avita: Well-Positioned for Growth o Supportive institutional shareholders o Qualified and aligned Board o Experienced and committed management team o Transformative platform technology & focused commercialisation strategy • Now on a clear course for FDA approval for key burn indication • Gai
Slide 27: 27
27